• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
News and impact
NIHR Biomedical Research Centre Leicester

NIHR Biomedical Research Centre Leicester

  • Home
  • About Us
    • Leadership Team
    • Our Impact
    • Our NIHR infrastructure
    • Governance
    • Inclusion
    • Strategies
    • Contact us
  • Our Research
    • Our Impact
    • Spotlight on our researchers
    • Cardiovascular
    • Data Innovation for Multiple Long-Term Health Conditions and Ethnic Health
    • Environment
    • Lifestyle
    • Personalised Cancer Prevention and Treatment
    • Respiratory and Infection
  • Patients and Public
    • Get Involved
    • Upcoming Public Involvement opportunities
    • Our approach to Public Involvement
    • Join the BioResource and Be Part of Research
    • Taking part in Clinical Trials
  • Industry and Partners
    • What we offer to industry
    • Collaborate with the Leicester BRC
    • Our partnerships
      • The NIHR Diet and Activity Research Translation (DART) Collaboration
  • For Researchers
    • Training
    • The Internal Resource Hub
    • Acknowledging and communicating your research
    • Guidance on Public Involvement (PPIE) for researchers
    • Advancing inclusion: transforming research culture in Leicester and beyond
    • PPI for Statistical Methodology and Research Techniques
  • News and Impact

How families are solving the mystery of a dangerous heart condition

Feb 25, 2022

Bicuspid aortic valve or BAV is the most common congenital heart condition and half of all people born with it end up needing open heart surgery. Yet many people don’t even know they have it.

BAV usually has no symptoms until later in life, when it resembles heart failure. People experience symptoms like chest pain or shortness of breath and seek medical help. During hospital tests for these they will find out about the condition they were born with.

Around 1 in 100 people are born with BAV, about the same number born with green eyes. People with BAV only have two segments in their aortic valve, which usually has three. These are more likely to weaken over time leading to illness. It is not clear what causes BAV or if there is any way to identify who will get ill or need surgery because of it.

Dr Radek Debiec

Dr Radek Debiec is working on solving this mystery.

“We think BAV is genetic, so if we can find the faulty genes that cause it we can identify people especially those who may eventually need surgery, ahead of time.”

Studies to find faulty genes usually compare people with the condition to healthy volunteers or a “standard” copy of DNA. However Radek’s team felt this was limited as it didn’t explain how BAV was inherited. They set up the BRAVE study in 2015 to study entire extended families to identify faulty genes.

“Usually the faulty gene is inherited from one of the parents and by looking at the family tree we can predict who else has it. Also the bigger the family the easier it is to find the gene that causes disease because it should be in all people with the condition, but absent in unaffected relatives.”

The BRAVE study is thought to be the biggest collection of extended families with BAV in the UK, but it hasn’t been an easy journey.

“Members of the family do not usually live in the same house, city or even country. We’ve had to adapt by sending blood samples by courier! We also have to work with many other hospitals to get heart scans of all the family members, and sometimes we have to wait for children to grow older as we can only recruit children over 10 years old. That is why it is important that our study continues long-term; so we can follow these families and be sure we’ve found the right genes.”

Despite the challenges, Radek is keen to go further to understand the genetic causes of BAV.

“The power of any genetic study lies in numbers. A new potential faulty gene discovered in one family needs to be confirmed, so we have to find another family with a defect in the same gene.

“These families are helping us give patients more answers and better ways to prepare. We hope our findings could even help other scientists develop treatment that will reduce these risks in the first place.

“We’re receiving more and more referrals from patients across the entire UK. I am currently applying for Intermediate BHF Clinical Research Fellowship. If successful I will develop a National Recruitment Program to expand this study even further.”

Dr Radek Debiec is an Academic Clinical Fellow at University of Leicester and part of the research team for the BRAVE study.

Category: BlogTag: blog, cardiovascular, genetic

Sidebar

Recent News

Leicester health specialists receive NIHR prizes for excelling in their fields

Respiratory researcher awarded Asthma + Lung UK Junior Fellowship

Weight-loss drug users turn to social media over doctors for advice

Read more news stories

The NIHR Leicester BRC is part of the NIHR and hosted by the University Hospitals of Leicester NHS Trust in partnership with the University of Leicester,  Loughborough University and the University Hospitals of the Northamptonshire NHS Group.

Get in touch

NIHR Leicester Biomedical Research Centre

University Hospitals of Leicester NHS Trust
Research & Innovation
Leicester General Hospital
Gwendolen Road
Leicester, LE5 4PW

Contact us

Our Research

Spotlight on our researchers

Cardiovascular

Data Innovation for Multiple Long-Term Health Conditions and Ethnic Health

Environment

Personalised Cancer Prevention and Treatment

Lifestyle

Respiratory and Infection

About BRC

Our NIHR infrastructure

BRC clinical research during COVID-19

Our 2022 – 2028 strategy documents

Governance

Useful links

Our partnerships

Inclusion

Privacy notice

Cookie Policy

Copyright © NIHR Biomedical Research Centre: Leicester

  • LinkedIn
  • X
  • Facebook
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}